Why Telix is taking PSMA-PET deeper into minimally invasive prostate cancer treatment
Prostate ablation is getting more precise. Telix wants PSMA-PET to become the imaging layer that helps clinicians decide where to treat.
Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane
Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.
What Plus Therapeutics Inc.’s SpectronRx partnership reveals about radiopharmaceutical manufacturing readiness
Discover how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing for pivotal trials and what it means for radiopharmaceutical innovation.
How Telix Pharmaceuticals Limited may be building a stronger neuro-oncology diagnostics franchise
Telix Pharmaceuticals Limited’s TLX101-Px NDA has been accepted by the FDA. Discover what this means for glioma imaging and the September decision.